Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2025-02-04 00:00:00 ET · period of report 2025-01-31 · accession 0001415889-25-003063 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-04 | 2025-02-03 | TVTX | Heerma Peter | Chief COMMERCIAL Off | S - Sale | $20.12 | -5,166 | 122.7K | -4% | -$103.9K |
| D | 2025-02-04 | 2025-01-31 | TVTX | Heerma Peter | Chief COMMERCIAL Off | A - Grant | $0.00 | +21.5K | 127.9K | +20% | $0 |
| D | 2025-02-04 | 2025-01-31 | TVTX | Heerma Peter | Chief COMMERCIAL Off | A - Grant | $0.00 | +58.0K | 58.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-03 | S | D | 5,166 | $20.12 | 122,708 | D | — | — | |
| 2 | Common | Common Stock | 2025-01-31 | A | A | 21,500 | $0.00 | 127,874 | D | — | — | |
| 3 | Derivative | Employee stock option (right to buy) | 2025-01-31 | A | A | 58,000 | $0.00 | 58,000 | D | $20.46 · — to 2035-01-31 | 58,000 Common Stock | (F3) One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter. |